Erin Lavelle
No más puestos en curso
Fortuna: - $ al 29/02/2024
Perfil
Erin M.
Lavelle is on the board of Neoleukin Therapeutics, Inc.
Ms. Lavelle previously was Executive VP, Chief Operating & Financial Officer at Eliem Therapeutics, Inc., General Manager at Amgen, Inc. and Chief Operating Officer of Lundbeck Seattle BioPharmaceuticals, Inc.
Erin M.
Lavelle received an undergraduate degree from Yale University.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Antiguos cargos conocidos de Erin Lavelle.
Empresas | Cargo | Fin |
---|---|---|
ELIEM THERAPEUTICS, INC. | Director of Finance/CFO | 10/03/2023 |
ALDER BIOPHARMACEUTICALS, INC. | Chief Operating Officer | 01/02/2020 |
AMGEN INC. | Corporate Officer/Principal | 01/03/2018 |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Director/Board Member | - |
NEUROGENE INC. | Director/Board Member | - |
Formación de Erin Lavelle.
Yale University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
AMGEN INC. | Health Technology |
Empresas privadas | 4 |
---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
Eliem Therapeutics, Inc. | |
Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |